Larimar Therapeutics Inc. (LRMR)
NASDAQ: LRMRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LRMR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $328.55M
- EPS (TTM)
- -$1.67
- Dividend yield
- None
- 52-week range
- 1.92 – 6.42
- Day range
- 2.96 – 3.22
- Volume / Avg
- 1.71M / 1.38M
- Beta
- —
- Shares outstanding
- 104.63M
52-week range
LRMR stock today
On Nov 20, LRMR ended the session at $3.14, shedding $0.08 (2.48%), versus the S&P 500's 3.70% decline. Shares are 51.1% below their 52-week high of $6.42, set on Feb 25, 2026 and 64.0% above the 52-week low of $1.92, in the middle of the past year's range. LRMR is down 17.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.8%.
Larimar Therapeutics has posted a net loss over the last twelve months (EPS of -$1.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Larimar Therapeutics
Company profileLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carole S. Ben-Maimon M.D.
- Headquarters
- Bala Cynwyd, PA
- Employees
- 71
- IPO year
- 2014
- Website
- larimartx.com
Financial highlights
Full financialsLarimar Therapeutics reported a net loss of $165.7 million, compared with a loss of $80.6 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-165.67M | $-80.60M | $-36.95M | $-35.35M | $-50.64M |
| EPS (diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$14.20+352.23%
- Strong buy 2
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.29 vs $-0.35
- Surprise
- +17.14%
LRMR news
All LRMR news- Larimar Therapeutics Completes BLA Submission for Nomlabofusp and Reports Third Quarter 2026 Financial ResultsNasdaqLRMR, LEN.B
- Larimar Therapeutics Reports Third Quarter 2026 Financial and Business UpdateGlobeNewswire
- Larimar Therapeutics, Inc. Completes Rolling BLA Submission for Nomlabofusp and Reports Preliminary Cash of $128.7 millionNasdaq
- Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia ResearchGlobeNewswire
- Tuesday Sector Leaders: Biotechnology, DrugsNasdaqMYGN, LRMR, ABOS, CPIX
Larimar Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs LRMR |
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs LRMR |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs LRMR |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs LRMR |
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs LRMR |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs LRMR |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs LRMR |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs LRMR |
Indexes, lists and sector
Larimar Therapeutics stock FAQ
What is Larimar Therapeutics's stock price today?
LRMR last traded at $3.14 as of Nov 20, 4:00 PM EST, down 2.48% on the day. Prices are delayed at least 15 minutes.
Who is Larimar Therapeutics's CEO?
Dr. Carole S. Ben-Maimon M.D. is the chief executive officer of Larimar Therapeutics Inc., which has about 71 employees.
What is the LRMR 52-week high?
The 52-week high for LRMR is $6.42 and the 52-week low is $1.92. The stock is currently 51.1% below its high.